Study supported by Washington University ICTS shows COVID-19 vaccine elicits antibodies in 90% taking immunosuppressants

COVID-19 vaccine elicits antibodies in 90% taking immunosuppressants

Nearly 90% of people taking immunosuppressants to treat autoimmune conditions produce an antibody response to COVID-19 vaccination, but the response is weaker than those generated by healthy people, according to a study by ICTS researchers at Washington University School of Medicine.

Publishing CTSA Program Hub’s Name
CTSA Program In Action Goals
Goal 2: Engage Patients and Communities in Every Phase of the Translational Process
Goal 3: Promote the Integration of Special and Underserved Populations in Translational Research Across the Human Lifespan
Goal 4: Innovate Processes to Increase the Quality and Efficiency of Translational Research, Particularly of Multisite Trials
Goal 5: Advance the Use of Cutting-Edge Informatics